Collects real-world data on cancer patients treated with radiotherapy
Gathers records of people with cancer who receive radiation treatment, without changing their care.
Plain-language title generated from the registry record
Registry title: E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
Key facts
- Where
- Badalona, Barcelona, Cartagena, Córdoba, Madrid, Pamplona, Salamanca, Terrassa, and Valencia, SpainSee the 15 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 and older with confirmed cancer who are planning to have radiotherapy. It collects real-world data and does not give any treatment.
- Age
- 12 years and older
- Sex
- All sexes can join.
- Disease stage
- Cancer confirmed by pathology (lab examination of tissue).
Main reasons for not taking part
- The patient does not fit at least one of the study's cohorts.
- No written informed consent.
- No radiotherapy is planned.
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How old is the patient who may join a trial?
Source: NCT03818503, who can take part
Where in Spain
- ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia)Badalona, SpainContact: EORTC HQTaking people
- Hospital de la Santa Creu i Sant PauBarcelona, SpainContact: EORTC HQTaking people
- Hospital Universitari Vall d'Hebron -Vall d'Hebron Institut OncologiaBarcelona, SpainContact: EORTC HQTaking people
- Hospital General Universitario Santa LuciaCartagena, SpainContact: EORTC HQTaking people
- Hospital Universitario Reina SofiaCórdoba, SpainContact: EORTC HQTaking people
- Hospital Universitario de la PrincesaMadrid, SpainContact: EORTC HQTaking people
- Hospital Universitario La PazMadrid, SpainContact: EORTC HQTaking people
- Hospital Universitario Ramón y CajalMadrid, SpainContact: EORTC HQTaking people
- Hospitales HM Sanchinarro-CIOCCMadrid, SpainContact: EORTC HQTaking people
- Hospital Universitario San CarlosMadrid, SpainContact: EORTC HQNo longer taking part
- Hospital Universitario de NavarraPamplona, SpainContact: EORTC HQNo longer taking part
- Hospital Universitario de Salamanca (430)Salamanca, SpainContact: EORTC HQTaking people
- Hospital Consorci Sanitari De TerrassaTerrassa, SpainContact: EORTC HQTaking people
- Hospital Clinico Universitario de ValenciaValencia, SpainContact: EORTC HQTaking people
- Hospital Universitario la FeValencia, SpainContact: EORTC HQTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- European Organisation for Research and Treatment of Cancer - EORTC
- Trial code
- NCT03818503
- Record updated
- 21 March 2025
- Original description
The primary objective is the collection of real-world data of cancer patients treated with radiotherapy, to support radiotherapy research and to provide evidence of the role of radiation oncology in a multidisciplinary approach. This is an open ended prospective non-interventional non-therapeutic multi-cohort study.Read full original descriptionShow less
E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
The primary objective is the collection of real-world data of cancer patients treated with radiotherapy, to support radiotherapy research and to provide evidence of the role of radiation oncology in a multidisciplinary approach. This is an open ended prospective non-interventional non-therapeutic multi-cohort study.
Inclusion: Pathologically confirmed cancer; Written informed consent for E²-RADIatE according to applicable legal and ethical requirements; Planned use of radiotherapy; Eligibility of the patient confirmed for at least one cohort confirmed; Patients of 12 years and older.